ADORA2A and neoplasm: In prospective clinical trial investigating adenosine pathway inhibitors, inhibition of the CD39/CD73/A2AR pathway was shown to increase immune cell activation, expand T cell repertoire in peripheral blood, and also increase T cell infiltration in tumor biopsy samples [132].